FAYETTEVILLE, Ark and BETHEL, Conn., March 18,
2025 /PRNewswire/ -- SFC Fluidics, Inc. ("SFC") and
Duracell U.S. Operations, Inc. ("Duracell") are collaborating to
efficiently deliver power to SFC's dual-hormone insulin and
glucagon delivery pod. The goal of this collaboration is to
integrate long-lasting, efficient power solutions into cutting-edge
wearable drug delivery systems targeting the treatment of
diabetes.
SFC has developed a miniaturized dual hormone pumping system,
called Gemini™, for high-accuracy drug delivery. This discrete
patch pump delivers both insulin to reduce high blood sugar
(hyperglycaemia) and glucagon to increase low blood sugar
(hypoglycaemia), acting as an artificial pancreas to maintain
stable blood glucose levels. The compact design is suitable for
children and adolescents, offering precise dosing even at low
levels. At the core of Gemini™ is ePump®, an advanced microfluidic
pumping system that ensures accurate delivery of small doses of
insulin and glucagon, surpassing the resolution limits of other
devices. The system enhances patient safety by virtually
eliminating accidental dosing.
SFC is excited to work with Duracell because Duracell's power
solutions are engineered to meet the demands of devices like the
Gemini™ ePump®, which require greater battery power in small,
lightweight sizes. "Our array of innovations, such as the ePump®,
could effectively eliminate 95% of over and under dispenses of
insulin. We are encouraged that our relationship with Duracell
continues to progress towards a meaningful goal of a marketed
artificial pancreas in the US," comments Anthony Cruz, CEO of SFC Fluidics.
Duracell, as one of the leading global battery brands, looks for
opportunities to apply its innovation in advancing current and
future devices. "Is there anything more rewarding than producing
battery innovations that help improve the lives of people?" asks
Gulhande Sanay, President of Duracell Future Innovations. "I am
inspired by our collaboration with SFC, a medical device company on
a mission to advance healthcare. Together, we look forward to the
commercialization of the Gemini™ pod and system."
SFC Fluidics, Inc. has a mission to advance healthcare
and improve quality of life through our enabling microfluidic
technologies. The company's vision is to become a recognized global
leader in drug delivery, with a focus on diabetes, where our unique
product lines improve lifestyle and affordability. SFC
Fluidics® is a VIC Technology Venture Development™
portfolio company. SFC Fluidics would like to acknowledge
the National Institutes of Health, including the National Institute
of Diabetes and Digestive and Kidney Diseases, for help in funding
the development of various aspects of the Gemini pod.
Duracell U.S. Operations, Inc. is a global leader in
the primary battery market with a commitment to quality and
reliability to consumers and partners. The iconic Duracell brand is
known to the world over. Duracell products serve as the heart of
devices that keep people connected, protect their families,
entertain them, and simplify their increasingly mobile lifestyles.
The long-lasting battery technology allows consumers to live life
without limits. Duracell is part of Berkshire Hathaway Inc.
(NYSE-BRK.A, BRK.B), a $250B holding
company owning subsidiaries that engage in diverse business
activities. Visit www.duracell.com for more information;
follow the company on Twitter.com/Duracell, Instagram.com/Duracell
and like it on Facebook.com/Duracell.
For more information please contact:
info@ssfcfluidics.com
duracellmedia@citizenrelations.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sfc-fluidics-collaborating-with-duracell-to-power-innovative-diabetes-devices-302403332.html
SOURCE SFC Fluidics
